It is very uncertain whether cyclophosphamide changes adverse effects: severe infection compared with chlorambucil (very low certainty).
It is very uncertain whether cyclophosphamide changes adverse effects: hair loss compared with chlorambucil (very low certainty).
Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in complete remission: FSGS compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).
Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).
Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).